• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Johnson & Johnson Reports Q4 and Full-Year 2024 Results

    1/22/25 6:20:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $JNJ alert in real time by email
    • 2024 Fourth-Quarter reported sales growth of 5.3% to $22.5 Billion with operational growth of 6.7%* and adjusted operational growth of 5.7%*
    • 2024 Fourth-Quarter Earnings per share (EPS) of $1.41 and Adjusted EPS of $2.04, both include $(0.22) due to acquired IPR&D charges related to V-Wave acquisition
    • 2024 Full-Year reported sales growth of 4.3% to $88.8 Billion with operational growth of 5.9%* and adjusted operational growth of 5.4%*. Operational growth excluding COVID-19 Vaccine of 7.0%*
    • 2024 Full-Year Earnings per share (EPS) of $5.79 and Adjusted EPS of $9.98, both include $(0.67) due to acquired IPR&D charges on various transactions throughout the year
    • Significant pipeline progress including RYBREVANT + LAZCLUZE overall survival data, initiation of TAR-200 submission, and approval of investigational device exemption for our general surgery robotic system, OTTAVA
    • Company issues guidance for 2025 with operational sales5 growth of 2.5% - 3.5%* and adjusted operational EPS of $10.75 - $10.95, reflecting strong growth of 8.7%* at the mid-point

    Johnson & Johnson (NYSE:JNJ) today announced results for fourth-quarter and full year 2024. "2024 was a transformative year for Johnson & Johnson, marked by strong growth, an accelerating pipeline and industry-leading investments in innovation," said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "As a healthcare company, with a disease-centric approach, we are improving the standard of care in a broad range of diseases with high unmet need, including multiple myeloma, lung cancer, inflammatory bowel disease, and heart failure. With our strong financial foundation, differentiated portfolio and robust pipeline, we are well positioned to sustain the high pace of growth and innovation that is the hallmark of Johnson & Johnson."

    Unless otherwise noted, the financial results and earnings guidance included below reflect the continuing operations of Johnson & Johnson.

    Overall financial results

     

    Q4

     

    Full Year

    ($ in Millions, expect EPS)

    2024

     

    2023

     

    % Change

     

    2024

     

    2023

     

    % Change

    Reported Sales

    $22,520

     

    $ 21,395

     

    5.3%

     

    $88,821

     

    $ 85,159

     

    4.3%

    Net Earnings

    $3,431

     

    $4,132

     

    (17.0)%

     

    $14,066

     

    $13,326

     

    5.6%

    EPS (diluted)

    $1.41

     

    $1.70

     

    (17.1)%

     

    $5.79

     

    $5.20

     

    11.3%

     

     

     

     

     

     

     

     

     

     

     

     

     

    Q4

     

    Full Year

    Non-GAAP* ($ in Millions, except EPS)

    2024

     

    2023

     

    % Change

     

    2024

     

    2023

     

    % Change

    Operational Sales1,2

     

     

     

     

    6.7%

     

     

     

     

     

    5.9%

    Adjusted Operational Sales1,3

     

     

     

     

    5.7%

     

     

     

     

     

    5.4%

    Adjusted Operational Sales1,3 ex. COVID-19 Vaccine

     

     

     

     

    5.9%

     

     

     

     

     

    6.5%

    Adjusted Net Earnings1,4

    $4,946

     

    $5,562

     

    (11.1)%

     

    $ 24,242

     

    $ 25,409

     

    (4.6)%

    Adjusted EPS (diluted)1,4

    $2.04

     

    $2.29

     

    (10.9)%

     

    $9.98

     

    $9.92

     

    0.6%

    Free Cash Flow6,7

     

     

     

     

     

     

    ~$19,800

     

    $18,248

     

     

    1

    Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules

    2

    Excludes the impact of translational currency

    3

    Excludes the net impact of acquisitions and divestitures and translational currency

    4

    Excludes intangible amortization expense and special items

    5

    Excludes COVID-19 Vaccine

    6

    Non-GAAP measure; defined as cash flow from operating activities, less additions to property, plant and equipment. Cash flow from operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings.

    7

    Full year 2024 is estimated as of January 22, 2025. Full year 2023 includes approximately 8 months contribution from the Consumer Health segment.

    Note: values may have been rounded

    Regional sales results

    Q4

     

     

     

     

     

     

    % Change

     

     

    ($ in Millions)

    2024

     

    2023

     

    Reported

     

    Operational1,2

     

    Currency

     

    Adjusted

    Operational1,3

    U.S.

    $13,204

    $12,009

    10.0%

    10.0

    -

    8.6

    International

    9,316

    9,386

    (0.7)

    2.5

    (3.2)

    2.0

    Worldwide

    $22,520

    $21,395

    5.3%

    6.7

    (1.4)

    5.7

     

     

     

     

     

     

     

    Full Year

     

     

     

     

     

     

    % Change

     

     

    ($ in Millions)

    2024

     

    2023

     

    Reported

     

    Operational1,2

     

    Currency

     

    Adjusted

    Operational1,3

    U.S.

    $50,302

    $46,444

    8.3%

    8.3

    -

    7.6

    International

    38,519

    38,715

    (0.5)

    2.9

    (3.4)

    2.7

    Worldwide

    $88,821

    $85,159

    4.3%

    5.9

    (1.6)

    5.4

    1

    Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules

    2

    Excludes the impact of translational currency

    3

    Excludes the net impact of acquisitions and divestitures and translational currency

    Note: values may have been rounded

    Segment sales results

    Q4

     

     

     

     

     

     

    % Change

     

     

    ($ in Millions)

    2024

     

    2023

     

    Reported

     

    Operational1,2

     

    Currency

     

    Adjusted

    Operational1,3

    Innovative Medicine

    $14,332

     

    $13,722

     

    4.4%

     

    6.1

     

    (1.7)

     

    6.3

    MedTech

    8,188

     

    7,673

     

    6.7

     

    7.6

     

    (0.9)

     

    4.6

    Worldwide

    $22,520

     

    $21,395

     

    5.3%

     

    6.7

     

    (1.4)

     

    5.7

    Full Year

     

     

     

     

     

     

    % Change

     

     

    ($ in Millions)

    2024

     

    2023

     

    Reported

     

    Operational1,2

     

    Currency

     

    Adjusted

    Operational1,3

    Innovative Medicine

    $56,964

    $54,759

    4.0%

    5.7

    (1.7)

    5.8

    MedTech

    31,857

    30,400

    4.8

    6.2

    (1.4)

    4.7

    Worldwide

    $88,821

    $85,159

    4.3%

    5.9

    (1.6)

    5.4

    1

    Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules

    2

    Excludes the impact of translational currency

    3

    Excludes the net impact of acquisitions and divestitures and translational currency

    Note: values may have been rounded

    Full year 2024 segment commentary:

    Operational sales* reflected below excludes the impact of translational currency.

    Innovative Medicine

    Innovative Medicine worldwide operational sales, excluding the COVID-19 Vaccine, grew 7.5%*. Growth was driven primarily by DARZALEX (daratumumab), ERLEADA (apalutamide), CARVYKTI (ciltacabtagene autoleucel), and Other Oncology in Oncology, TREMFYA (guselkumab) in Immunology, and SPRAVATO (esketamine) in Neuroscience. Growth was partially offset by STELARA (ustekinumab) in Immunology and Other Neuroscience in Neuroscience. Including the COVID-19 Vaccine, Innovative Medicine worldwide operational sales grew 5.7%*.

    MedTech

    MedTech worldwide operational sales grew 6.2%*, with net acquisitions and divestitures positively impacting growth by 1.5%. Growth was driven primarily by electrophysiology products and Abiomed in Cardiovascular, previously referred to as Interventional Solutions, and wound closure products in General Surgery.

    Full-year 2025 guidance:

    Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses, and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP.

    ($ in Billions, except EPS)

     

    January 2025

    Adjusted Operational Sales1,2,5

    Change vs. Prior Year / Mid-point

     

    2.0% – 3.0% / 2.5%

    Operational Sales2,5 / Mid-point

    Change vs. Prior Year / Mid-point

     

    $90.9B – $91.7B / $91.3B

    2.5% – 3.5% / 3.0%

    Estimated Reported Sales3,5/ Mid-point

    Change vs. Prior Year / Mid-point

     

    $89.2B – $90.0B / $89.6B

    0.5% – 1.5% / 1.0%

    Adjusted Operational EPS (Diluted)2,4 / Mid-point

    Change vs. Prior Year / Mid-point

     

    $10.75 – $10.95 / $10.85

    7.7% – 9.7% / 8.7%

    Adjusted EPS (Diluted)3,4 / Mid-point

    Change vs. Prior Year / Mid-point

     

    $10.50 – $10.70 / $10.60

    5.2% – 7.2% / 6.2%

    1

    Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures

    2

    Non-GAAP financial measure; excludes the impact of translational currency

    3

    Calculated using Euro Average Rate: January 2025 = $1.04 (Illustrative purposes only)

    4

    Non-GAAP financial measure; excludes intangible amortization expense and special items

    5

    Excludes COVID-19 Vaccine

    Note: percentages may have been rounded

    Other modeling considerations will be provided on the webcast.

    Notable announcements in the quarter:

    The information contained in this section should be read together with Johnson & Johnson's other disclosures filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. The reader is also encouraged to review all other news releases and information available in the Investor Relations section of the company's website at News Releases, as well as Innovative Medicine News Center, MedTech News & Events, and www.factsabouttalc.com.

    Regulatory

    SPRAVATO (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression1

    Press Release

     

    European Commission approves LAZCLUZE (lazertinib) in combination with RYBREVANT (amivantamab) for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer1

    Press Release

     

    New Drug Application initiated with U.S. FDA for TAR-200, the first and only intravesical drug releasing system for patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer1

    Press Release

     

    Johnson & Johnson MedTech Announces CE Mark Approval for Dual Energy THERMOCOOL SMARTTOUCH SF Catheter1

    Press Release

     

    Nipocalimab granted U.S. FDA Priority Review for the treatment of generalized myasthenia gravis1

    Press Release

    Johnson & Johnson's Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer's Disease1

    Press Release

    European Commission approves RYBREVANT (amivantamab) in combination with LAZCLUZE (lazertinib) for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer

    Press Release

    Johnson & Johnson submits application to the European Medicines Agency seeking approval of a new indication for IMBRUVICA (ibrutinib) in adult patients with previously untreated mantle cell lymphoma (MCL) who are eligible for autologous stem cell transplant

    Press Release

    U.S. FDA Expands Indication for Impella Heart Pumps to Treat Pediatric Patients

    Press Release

    Johnson & Johnson seeks U.S. FDA approval for first pediatric indications for TREMFYA (guselkumab)

    Press Release

    Johnson & Johnson seeks U.S. FDA approval for subcutaneous induction regimen of TREMFYA (guselkumab) in ulcerative colitis, a first for an IL-23 inhibitor

    Press Release

    Johnson & Johnson MedTech Receives IDE Approval for OTTAVA Robotic Surgical System

    Press Release

    Nipocalimab is the first and only investigational therapy granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjögren's disease

    Press Release

    Johnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO / DARZALEX as subcutaneous monotherapy for high-risk smoldering multiple myeloma

    Press Release

    DARZALEX (daratumumab)-SC based quadruplet regimen approved by the European Commission for patients with newly diagnosed multiple myeloma who are transplant-eligible

    Press Release

    Data Releases

    RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) show statistically significant and clinically meaningful improvement in overall survival versus osimertinib1

    Press Release

     

    Johnson & Johnson to showcase strength of its broad hematology portfolio and pipeline at the 2024 American Society of Hematology Annual Meeting

    Press Release

    Icotrokinra delivered an industry-leading combination of significant skin clearance with demonstrated tolerability in a once daily pill in Phase 3 topline results

    Press Release

    Johnson & Johnson advances leadership in rheumatic disease innovation with 43 abstracts at ACR 2024

    Press Release

    Shockwave Medical Unveils First Clinical Outcomes of New IVL Platform in Late-Breaking Presentation at VIVA 2024

    Press Release

    TREMFYA (guselkumab) is the first and only IL-23 inhibitor to demonstrate robust results with a fully subcutaneous regimen in both induction and maintenance in Crohn's disease

    Press Release

    New SPECTREM study findings reveal TREMFYA (guselkumab) effectively clears overlooked and undertreated plaque psoriasis

    Press Release

    Johnson & Johnson highlights innovative neuropsychiatry portfolio and pipeline at Psych Congress

    Press Release

    Nipocalimab demonstrates sustained disease control in adolescents living with generalized myasthenia gravis in Phase 2/3 study

    Press Release

    Product Launch

    MENTOR MemoryGel Enhance Breast Implant Receives FDA Approval for Largest Size Breast Implants for Reconstruction

    Press Release

    Johnson & Johnson MedTech Receives FDA Approval for the VARIPULSE Pulsed Field Ablation Platform for the Treatment of Atrial Fibrillation2

    Press Release

    Other

    Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.1

    Press Release

    1

    Subsequent to the quarter

    2

    On January 5, 2025, Johnson & Johnson MedTech temporarily paused the U.S. External Evaluation and all U.S. VARIPULSE cases. More information can be found in the Statement on VARIPULSE.

    Webcast information:

    Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:00 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website. A replay and podcast will be available approximately two hours after the live webcast in the Investor Relations section of the company's website at events-and-presentations.

    About Johnson & Johnson:

    At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at www.jnj.com.

    Non-GAAP financial measures:

    * "Operational sales growth" excluding the impact of translational currency, "adjusted operational sales growth" excluding the net impact of acquisitions and divestitures and translational currency, as well as "adjusted net earnings", "adjusted diluted earnings per share" and "adjusted operational diluted earnings per share" excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the company's website at quarterly results.

    Copies of the financial schedules accompanying this earnings release are available on the company's website at quarterly results. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including adjusted income before tax by segment, an Innovative Medicine pipeline of selected compounds in late stage development and a copy of today's earnings call presentation can also be found in the Investor Relations section of the company's website at quarterly results.

    Note to investors concerning forward-looking statements:

    This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, and market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies; and the Company's ability to realize the anticipated benefits from the separation of Kenvue Inc. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

    Johnson & Johnson and Subsidiaries
    Supplementary Sales Data
     
    (Unaudited; Dollars in Millions) FOURTH QUARTER TWELVE MONTHS
    Percent Change Percent Change

    2024

     

    2023

     

    Total

    Operations

    Currency

     

    2024

    2023

    Total Operations Currency
    Sales to customers by
    segment of business
     
    Innovative Medicine (1)
    U.S.

    $

    8,977

    8,079

    11.1

     

    %

    11.1

     

    -

     

    $

    33,970

    31,169

    9.0

     

    %

    9.0

    -

     

    International

     

    5,355

    5,643

    (5.1

    )

    (1.0

    )

    (4.1

    )

     

    22,994

    23,590

    (2.5

    )

    1.3

    (3.8

    )

     

    14,332

    13,722

    4.4

     

    6.1

     

    (1.7

    )

     

    56,964

    54,759

    4.0

     

    5.7

    (1.7

    )

     
    Innovative Medicine excluding COVID-19 Vaccine (1)
    U.S.

     

    8,977

    8,079

    11.1

     

    11.1

     

    -

     

     

    33,970

    31,169

    9.0

     

    9.0

    -

     

    International

     

    5,355

    5,599

    (4.4

    )

    (0.3

    )

    (4.1

    )

     

    22,796

    22,473

    1.4

     

    5.5

    (4.1

    )

     

    14,332

    13,678

    4.8

     

    6.5

     

    (1.7

    )

     

    56,766

    53,642

    5.8

     

    7.5

    (1.7

    )

     
    MedTech
    U.S.

     

    4,227

    3,930

    7.6

     

    7.6

     

    -

     

     

    16,332

    15,275

    6.9

     

    6.9

    -

     

    International

     

    3,961

    3,743

    5.8

     

    7.6

     

    (1.8

    )

     

    15,525

    15,125

    2.6

     

    5.4

    (2.8

    )

     

    8,188

    7,673

    6.7

     

    7.6

     

    (0.9

    )

     

    31,857

    30,400

    4.8

     

    6.2

    (1.4

    )

     
    U.S.

     

    13,204

    12,009

    10.0

     

    10.0

     

    -

     

     

    50,302

    46,444

    8.3

     

    8.3

    -

     

    International

     

    9,316

    9,386

    (0.7

    )

    2.5

     

    (3.2

    )

     

    38,519

    38,715

    (0.5

    )

    2.9

    (3.4

    )

    Worldwide

     

    22,520

    21,395

    5.3

     

    6.7

     

    (1.4

    )

     

    88,821

    85,159

    4.3

     

    5.9

    (1.6

    )

     
    U.S.

     

    13,204

    12,009

    10.0

     

    10.0

     

    -

     

     

    50,302

    46,444

    8.3

     

    8.3

    -

     

    International

     

    9,316

    9,342

    (0.3

    )

    2.9

     

    (3.2

    )

     

    38,321

    37,598

    1.9

     

    5.5

    (3.6

    )

    Worldwide excluding COVID-19 Vaccine (1)

    $

    22,520

    21,351

    5.5

     

    %

    6.9

     

    (1.4

    )

    $

    88,623

    84,042

    5.5

     

    %

    7.0

    (1.5

    )

     
    Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
     
    (1) Refer to supplemental sales information schedules
    Johnson & Johnson and Subsidiaries
    Supplementary Sales Data
     
    (Unaudited; Dollars in Millions)

    FOURTH QUARTER

     

    TWELVE MONTHS

     

     

     

     

    Percent Change

     

     

     

     

     

    Percent Change

    2024

     

    2023

     

    Total

     

    Operations

     

    Currency

     

    2024

     

    2023

     

    Total

     

    Operations

    Currency

    Sales to customers by
    geographic area
     
    U.S.

    $

    13,204

    12,009

    10.0

    %

    10.0

     

    -

     

    $

    50,302

    46,444

    8.3

    %

    8.3

     

    -

     

     
    Europe

     

    4,921

    4,962

    (0.8

    )

    (0.2

    )

    (0.6

    )

     

    20,212

    20,410

    (1.0

    )

    (0.6

    )

    (0.4

    )

    Western Hemisphere excluding U.S.

     

    1,135

    1,166

    (2.7

    )

    17.6

     

    (20.3

    )

     

    4,714

    4,549

    3.6

     

    20.4

     

    (16.8

    )

    Asia-Pacific, Africa

     

    3,260

    3,258

    0.1

     

    0.9

     

    (0.8

    )

     

    13,593

    13,756

    (1.2

    )

    2.3

     

    (3.5

    )

    International

     

    9,316

    9,386

    (0.7

    )

    2.5

     

    (3.2

    )

     

    38,519

    38,715

    (0.5

    )

    2.9

     

    (3.4

    )

     
    Worldwide

    $

    22,520

    21,395

    5.3

    %

    6.7

     

    (1.4

    )

    $

    88,821

    85,159

    4.3

    %

    5.9

     

    (1.6

    )

     
     
    Johnson & Johnson and Subsidiaries
    Supplementary Sales Data
     
    (Unaudited; Dollars in Millions)

    FOURTH QUARTER

     

    TWELVE MONTHS

     

     

     

     

    Percent Change

     

     

     

     

     

    Percent Change

    2024

     

    2023

     

    Total

     

    Operations

     

    Currency

     

    2024

     

    2023

     

    Total

     

    Operations

    Currency

    Sales to customers by
    geographic area (ex. COVID-19 Vaccine)
     
    U.S.*

    $

    13,204

    12,009

    10.0

    %

    10.0

     

    -

     

    $

    50,302

    46,444

    8.3

    %

    8.3

     

    -

     

     
    Europe(1)

     

    4,921

    4,918

    0.1

     

    0.7

     

    (0.6

    )

     

    20,014

    19,293

    3.7

     

    4.1

     

    (0.4

    )

    Western Hemisphere excluding U.S.*

     

    1,135

    1,166

    (2.7

    )

    17.6

     

    (20.3

    )

     

    4,714

    4,549

    3.6

     

    20.4

     

    (16.8

    )

    Asia-Pacific, Africa*

     

    3,260

    3,258

    0.1

     

    0.9

     

    (0.8

    )

     

    13,593

    13,756

    (1.2

    )

    2.3

     

    (3.5

    )

    International

     

    9,316

    9,342

    (0.3

    )

    2.9

     

    (3.2

    )

     

    38,321

    37,598

    1.9

     

    5.5

     

    (3.6

    )

     
    Worldwide

    $

    22,520

    21,351

    5.5

    %

    6.9

     

    (1.4

    )

    $

    88,623

    84,042

    5.5

    %

    7.0

     

    (1.5

    )

     
    Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
     
    (1) Refer to supplemental sales information schedules
    *No COVID-19 Vaccine sales
     
    Johnson & Johnson and Subsidiaries
    Condensed Consolidated Statement of Earnings
     
    (Unaudited; in Millions Except Per Share Figures) FOURTH QUARTER
     

    2024

     

    2023

     

    Percent

     

     

    Percent

     

     

     

    Percent

     

    Increase

    Amount

     

    to Sales

    Amount

     

    to Sales

    (Decrease)

    Sales to customers

    $

    22,520

     

    100.0

     

    $

    21,395

     

    100.0

     

    5.3

     

    Cost of products sold

     

    7,128

     

    31.6

     

     

    6,798

     

    31.8

     

    4.9

     

    Gross Profit

     

    15,392

     

    68.4

     

     

    14,597

     

    68.2

     

    5.4

     

    Selling, marketing and administrative expenses

     

    6,453

     

    28.6

     

     

    5,810

     

    27.1

     

    11.1

     

    Research and development expense

     

    5,298

     

    23.5

     

     

    4,480

     

    20.9

     

    18.3

     

    In-process research and development impairments

     

    17

     

    0.1

     

     

    58

     

    0.3

     

    Interest (income) expense, net

     

    (144

    )

    (0.6

    )

     

    (212

    )

    (1.0

    )

    Other (income) expense, net

     

    (161

    )

    (0.7

    )

     

    (421

    )

    (2.0

    )

    Restructuring

     

    42

     

    0.2

     

     

    56

     

    0.3

     

    Earnings before provision for taxes on income

     

    3,887

     

    17.3

     

     

    4,826

     

    22.6

     

    (19.5

    )

    Provision for taxes on income

     

    456

     

    2.1

     

     

    694

     

    3.3

     

    (34.3

    )

    Net earnings from Continuing Operations

    $

    3,431

     

    15.2

     

    $

    4,132

     

    19.3

     

    (17.0

    )

    Net earnings/(loss) from Discontinued Operations, net of tax

     

    -

     

     

    (83

    )

    Net earnings

    $

    3,431

     

    $

    4,049

     

     
    Net earnings per share (Diluted) from Continuing Operations

    $

    1.41

     

    $

    1.70

     

    (17.1

    )

    Net earnings/(loss) per share (Basic) from Discontinued Operations*

    $

    -

     

    $

    (0.03

    )

     
    Average shares outstanding (Diluted)

     

    2,427.1

     

     

    2,430.7

     

     
    Effective tax rate from Continuing Operations

     

    11.7

     

    %

     

    14.4

     

    %

     
    Adjusted earnings from Continuing Operations before provision for taxes and net earnings (1)
    Earnings before provision for taxes on income from Continuing Operations

    $

    5,421

     

    24.1

     

    $

    6,237

     

    29.2

     

    (13.1

    )

    Net earnings from Continuing Operations

    $

    4,946

     

    22.0

     

    $

    5,562

     

    26.0

     

    (11.1

    )

    Net earnings per share (Diluted) from Continuing Operations

    $

    2.04

     

    $

    2.29

     

    (10.9

    )

    Effective tax rate from Continuing Operations

     

    8.8

     

    %

     

    10.8

     

    %

    * Basic shares of 2,407.2 are used to calculate loss per share in the fourth quarter of 2023 as use of diluted shares when in a loss position would be anti-dilutive.
    (1) See Reconciliation of Non-GAAP Financial Measures.
     
    Johnson & Johnson and Subsidiaries
    Condensed Consolidated Statement of Earnings
     
    (Unaudited; in Millions Except Per Share Figures) TWELVE MONTHS
     

    2024

     

    2023

     

    Percent

     

     

    Percent

     

     

     

    Percent

     

    Increase

    Amount

     

    to Sales

    Amount

     

    to Sales

    (Decrease)

    Sales to customers

    $

    88,821

     

    100.0

     

    $

    85,159

     

    100.0

     

    4.3

     

    Cost of products sold

     

    27,471

     

    30.9

     

     

    26,553

     

    31.2

     

    3.5

     

    Gross Profit

     

    61,350

     

    69.1

     

     

    58,606

     

    68.8

     

    4.7

     

    Selling, marketing and administrative expenses

     

    22,869

     

    25.7

     

     

    21,512

     

    25.2

     

    6.3

     

    Research and development expense

     

    17,232

     

    19.4

     

     

    15,085

     

    17.7

     

    14.2

     

    In-process research and development impairments

     

    211

     

    0.2

     

     

    313

     

    0.4

     

    Interest (income) expense, net

     

    (577

    )

    (0.6

    )

     

    (489

    )

    (0.6

    )

    Other (income) expense, net

     

    4,694

     

    5.3

     

     

    6,634

     

    7.8

     

    Restructuring

     

    234

     

    0.3

     

     

    489

     

    0.6

     

    Earnings before provision for taxes on income

     

    16,687

     

    18.8

     

     

    15,062

     

    17.7

     

    10.8

     

    Provision for taxes on income

     

    2,621

     

    3.0

     

     

    1,736

     

    2.1

     

    51.0

     

    Net earnings from Continuing Operations

    $

    14,066

     

    15.8

     

    $

    13,326

     

    15.6

     

    5.6

     

    Net earnings from Discontinued Operations, net of tax

     

    -

     

     

    21,827

     

    Net earnings

    $

    14,066

     

    $

    35,153

     

     
    Net earnings per share (Diluted) from Continuing Operations

    $

    5.79

     

    $

    5.20

     

    11.3

     

    Net earnings per share (Diluted) from Discontinued Operations

    $

    -

     

    $

    8.52

     

     
    Average shares outstanding (Diluted)

     

    2,429.4

     

     

    2,560.4

     

     
    Effective tax rate from Continuing Operations

     

    15.7

     

    %

     

    11.5

     

    %

     
    Adjusted earnings from Continuing Operations before provision for taxes and net earnings (1)
    Earnings before provision for taxes on income from Continuing Operations

    $

    28,979

     

    32.6

     

    $

    29,811

     

    35.0

     

    (2.8

    )

    Net earnings from Continuing Operations

    $

    24,242

     

    27.3

     

    $

    25,409

     

    29.8

     

    (4.6

    )

    Net earnings per share (Diluted) from Continuing Operations

    $

    9.98

     

    $

    9.92

     

    0.6

     

    Effective tax rate from Continuing Operations

     

    16.3

     

    %

     

    14.8

     

    %

     
    (1) See Reconciliation of Non-GAAP Financial Measures.
    Johnson & Johnson and Subsidiaries
    Reconciliation of Non-GAAP Financial Measures
     
    Fourth Quarter Twelve Months Ended
    (Dollars in Millions Except Per Share Data)

    2024

    2023

    2024

    2023

    Net Earnings from Continuing Operations, after tax- as reported

    $3,431

    $4,132

    $14,066

    $13,326

     
    Pre-tax Adjustments
    Litigation related

    (16)

    166

    5,450

    7,152

    Intangible Asset Amortization expense

    1,171

    1,148

    4,526

    4,532

    COVID-19 Vaccine related costs 1

    23

    10

    100

    663

    Restructuring related 2

    62

    139

    269

    798

    Medical Device Regulation 3

    47

    88

    204

    311

    Acquisition, integration and divestiture related

    298

    237

    1,226

    339

    (Gains)/losses on securities

    (68)

    (435)

    306

    641

    IPR&D impairments

    17

    58

    211

    313

     
    Tax Adjustments
    Tax impact on special item adjustments 4

    (80)

    75

    (2,135)

    (2,694)

    Tax legislation and other tax related

    61

    (56)

    19

    28

    Adjusted Net Earnings from Continuing Operations, after tax

    $4,946

    $5,562

    $24,242

    $25,409

    Average shares outstanding (Diluted)

    2,427.1

    2,430.7

    2,429.4

    2,560.4

    Adjusted net earnings per share from Continuing Operations (Diluted)

    $2.04

    $2.29

    $9.98

    $9.92

    Operational adjusted net earnings per share from Continuing Operations (Diluted)

    $2.05

    $9.99

     
    Notes:

    1

    COVID-19 Vaccine related costs include remaining commitments and obligations, including external manufacturing network exit costs and required clinical trial expenses, associated with the Company's completion of its COVID-19 vaccine contractual commitments which was completed in Q4 2024.

     

    2

    In fiscal 2023, the company completed a prioritization of its research and development (R&D) investment within the Innovative Medicine segment to focus on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs within therapeutic areas. The R&D program exits are primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program, hepatitis and HIV development. The restructuring expense of $102 million Q4 2024 YTD and $55 million in the fiscal fourth quarter of 2023 ($479 million Q4 2023 YTD) includes the termination of partnered and non-partnered program costs, asset impairments and asset divestments. This program was completed in Q4 2024.

     

    In fiscal 2023, the company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The restructuring expense of $60 million in the fiscal fourth quarter of 2024 ($167 million Q4 2024 YTD) and $84 million in the fiscal fourth quarter of 2023 ($319 million Q4 2023 YTD) primarily includes costs related to the market and product exits.

     

    3

    European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company's previously registered products. MDR is a replacement of the existing European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical devices were required to comply with EU MDR beginning in May 2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on-going operations. The Company has excluded only external third-party regulatory and consulting costs from its MedTech operating segments' measures of profit and loss used for making operating decisions and assessing performance. The implementation was substantially completed as of Q4 2024, and ongoing costs will be reflected in MedTech's operating results beginning in 2025.

     

    4

    The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.
    Johnson & Johnson and Subsidiaries
    Reconciliation of Non-GAAP Financial Measure
     
    Adjusted Operational Sales Growth
    FOURTH QUARTER 2024 ACTUAL vs. 2023 ACTUAL
       
    Segments
     
    Innovative Medicine MedTech Total
     
    WW As Reported

    4.4

    %

    6.7

    %

    5.3

    %

    U.S.

    11.1

    %

    7.6

    %

    10.0

    %

    International

    (5.1

    )%

    5.8

    %

    (0.7

    )%

     
    WW Currency

    (1.7

    )

    (0.9

    )

    (1.4

    )

    U.S.

    -

     

    -

     

    -

     

    International

    (4.1

    )

    (1.8

    )

    (3.2

    )

     
    WW Operational

    6.1

    %

    7.6

    %

    6.7

    %

    U.S.

    11.1

    %

    7.6

    %

    10.0

    %

    International

    (1.0

    )%

    7.6

    %

    2.5

    %

     
    Shockwave

    (3.4

    )

    (1.2

    )

    U.S.

    (5.1

    )

    (1.7

    )

    International

    (1.5

    )

    (0.6

    )

     
    All Other Acquisitions and Divestitures (A&D)

    0.2

     

    0.4

     

    0.2

     

    U.S.

    0.1

     

    0.8

     

    0.3

     

    International

    0.3

     

    0.0

     

    0.1

     

     
    WW Adjusted Operational Ex A&D

    6.3

    %

    4.6

    %

    5.7

    %

    U.S.

    11.2

    %

    3.3

    %

    8.6

    %

    International

    (0.7

    )%

    6.1

    %

    2.0

    %

     
    COVID-19 Vaccine

    0.4

     

    0.2

     

    U.S.

    0.0

     

    0.0

     

    International

    0.7

     

    0.4

     

     
    WW Adjusted Operational Ex A&D & COVID-19 Vaccine

    6.7

    %

    4.6

    %

    5.9

    %

    U.S.

    11.2

    %

    3.3

    %

    8.6

    %

    International

    0.0

    %

    6.1

    %

    2.4

    %

     
     
    Note: Percentages are based on actual, non-rounded figures and may not sum
    Johnson & Johnson and Subsidiaries
    Reconciliation of Non-GAAP Financial Measure
     
    Adjusted Operational Sales Growth
    TWELVE MONTHS 2024 ACTUAL vs. 2023 ACTUAL
       
    Segments
     
    Innovative Medicine MedTech Total
     
    WW As Reported

    4.0

    %

    4.8

    %

    4.3

    %

    U.S.

    9.0

    %

    6.9

    %

    8.3

    %

    International

    (2.5

    )%

    2.6

    %

    (0.5

    )%

     
    WW Currency

    (1.7

    )

    (1.4

    )

    (1.6

    )

    U.S.

    -

     

    -

     

    -

     

    International

    (3.8

    )

    (2.8

    )

    (3.4

    )

     
    WW Operational

    5.7

    %

    6.2

    %

    5.9

    %

    U.S.

    9.0

    %

    6.9

    %

    8.3

    %

    International

    1.3

    %

    5.4

    %

    2.9

    %

     
    Shockwave

    (1.9

    )

    (0.7

    )

    U.S.

    (2.9

    )

    (1.0

    )

    International

    (0.8

    )

    (0.3

    )

     
    All Other Acquisitions and Divestitures (A&D)

    0.1

     

    0.4

     

    0.2

     

    U.S.

    0.1

     

    0.8

     

    0.3

     

    International

    0.2

     

    0.1

     

    0.1

     

     
    WW Adjusted Operational Ex A&D

    5.8

    %

    4.7

    %

    5.4

    %

    U.S.

    9.1

    %

    4.8

    %

    7.6

    %

    International

    1.5

    %

    4.7

    %

    2.7

    %

     
    COVID-19 Vaccine

    1.8

     

    1.1

     

    U.S.

    0.0

     

    0.0

     

    International

    4.2

     

    2.6

     

     
    WW Adjusted Operational Ex A&D & COVID-19 Vaccine

    7.6

    %

    4.7

    %

    6.5

    %

    U.S.

    9.1

    %

    4.8

    %

    7.6

    %

    International

    5.7

    %

    4.7

    %

    5.3

    %

     
    Note: Percentages are based on actual, non-rounded figures and may not sum

     

    REPORTED SALES vs. PRIOR PERIOD ($MM)

     

     

    REPORTED SALES vs. PRIOR PERIOD ($MM)

    FOURTH QUARTER

     

     

    TWELVE MONTHS

     

     

     

     

     

    % Change

     

     

     

     

     

     

    % Change

    INNOVATIVE MEDICINE SEGMENT (2)

     

    2024

     

    2023

     

    Reported

     

    Operational (1)

     

    Currency

     

     

    2024

     

    2023

     

    Reported

     

    Operational (1)

     

    Currency

     
    IMMUNOLOGY
    US

    $

    2,856

     

    3,033

    -5.9

    %

    -5.9

    %

    -

     

    $

    11,355

    11,539

    -1.6

    %

    -1.6

    %

    -

     

    Intl

     

    1,383

     

    1,562

    -11.5

    %

    -6.5

    %

    -5.0

    %

     

    6,473

    6,513

    -0.6

    %

    4.0

    %

    -4.6

    %

    WW

     

    4,238

     

    4,595

    -7.8

    %

    -6.1

    %

    -1.7

    %

     

    17,828

    18,052

    -1.2

    %

    0.4

    %

    -1.6

    %

    REMICADE
    US

     

    231

     

    294

    -21.4

    %

    -21.4

    %

    -

     

     

    1,009

    1,143

    -11.7

    %

    -11.7

    %

    -

     

    US Exports (3)

     

    9

     

    35

    -73.3

    %

    -73.3

    %

    -

     

     

    98

    147

    -33.0

    %

    -33.0

    %

    -

     

    Intl

     

    117

     

    100

    16.5

    %

    22.9

    %

    -6.4

    %

     

    497

    549

    -9.5

    %

    -5.0

    %

    -4.5

    %

    WW

     

    359

     

    429

    -16.5

    %

    -15.0

    %

    -1.5

    %

     

    1,605

    1,839

    -12.8

    %

    -11.4

    %

    -1.4

    %

    SIMPONI / SIMPONI ARIA
    US

     

    262

     

    258

    1.3

    %

    1.3

    %

    -

     

     

    1,082

    1,124

    -3.8

    %

    -3.8

    %

    -

     

    Intl

     

    321

     

    244

    32.1

    %

    44.2

    %

    -12.1

    %

     

    1,108

    1,073

    3.3

    %

    13.2

    %

    -9.9

    %

    WW

     

    583

     

    502

    16.2

    %

    22.1

    %

    -5.9

    %

     

    2,190

    2,197

    -0.3

    %

    4.5

    %

    -4.8

    %

    STELARA
    US

     

    1,699

     

    1,786

    -4.9

    %

    -4.9

    %

    -

     

     

    6,720

    6,966

    -3.5

    %

    -3.5

    %

    -

     

    Intl

     

    650

     

    967

    -32.7

    %

    -29.6

    %

    -3.1

    %

     

    3,641

    3,892

    -6.4

    %

    -3.3

    %

    -3.1

    %

    WW

     

    2,349

     

    2,753

    -14.7

    %

    -13.6

    %

    -1.1

    %

     

    10,361

    10,858

    -4.6

    %

    -3.4

    %

    -1.2

    %

    TREMFYA
    US

     

    654

     

    657

    -0.6

    %

    -0.6

    %

    -

     

     

    2,443

    2,147

    13.7

    %

    13.7

    %

    -

     

    Intl

     

    295

     

    252

    16.9

    %

    21.7

    %

    -4.8

    %

     

    1,227

    999

    22.8

    %

    27.6

    %

    -4.8

    %

    WW

     

    949

     

    910

    4.2

    %

    5.6

    %

    -1.4

    %

     

    3,670

    3,147

    16.6

    %

    18.1

    %

    -1.5

    %

    OTHER IMMUNOLOGY
    US

     

    0

     

    2

    * *

    -

     

     

    3

    11

    -74.1

    %

    -74.1

    %

    -

     

    Intl

     

    0

     

    0

    -

     

    -

     

    -

     

     

    0

    0

    -

     

    -

     

    -

     

    WW

     

    0

     

    2

    * * *

     

    3

    11

    -74.1

    %

    -74.1

    %

    -

     

    INFECTIOUS DISEASES
    US

     

    331

     

    353

    -6.4

    %

    -6.4

    %

    -

     

     

    1,354

    1,500

    -9.8

    %

    -9.8

    %

    -

     

    Intl

     

    443

     

    498

    -11.2

    %

    -9.8

    %

    -1.4

    %

     

    2,042

    2,918

    -30.0

    %

    -29.3

    %

    -0.7

    %

    WW

     

    774

     

    852

    -9.2

    %

    -8.4

    %

    -0.8

    %

     

    3,396

    4,418

    -23.1

    %

    -22.7

    %

    -0.4

    %

    COVID-19 VACCINE
    US

     

    0

     

    0

    -

     

    -

     

    -

     

     

    0

    0

    -

     

    -

     

    -

     

    Intl

     

    0

     

    44

    * * *

     

    198

    1,117

    -82.4

    %

    -82.4

    %

    0.0

    %

    WW

     

    0

     

    44

    * * *

     

    198

    1,117

    -82.4

    %

    -82.4

    %

    0.0

    %

    EDURANT / rilpivirine
    US

     

    7

     

    9

    -10.1

    %

    -10.1

    %

    -

     

     

    31

    35

    -10.0

    %

    -10.0

    %

    -

     

    Intl

     

    315

     

    299

    5.0

    %

    5.6

    %

    -0.6

    %

     

    1,241

    1,115

    11.2

    %

    11.2

    %

    0.0

    %

    WW

     

    322

     

    307

    4.6

    %

    5.1

    %

    -0.5

    %

     

    1,272

    1,150

    10.6

    %

    10.6

    %

    0.0

    %

    PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
    US

     

    321

     

    341

    -5.8

    %

    -5.8

    %

    -

     

     

    1,311

    1,446

    -9.4

    %

    -9.4

    %

    -

     

    Intl

     

    86

     

    98

    -12.9

    %

    -8.9

    %

    -4.0

    %

     

    401

    408

    -1.7

    %

    1.1

    %

    -2.8

    %

    WW

     

    407

     

    439

    -7.4

    %

    -6.5

    %

    -0.9

    %

     

    1,712

    1,854

    -7.7

    %

    -7.1

    %

    -0.6

    %

    OTHER INFECTIOUS DISEASES
    US

     

    1

     

    4

    -53.1

    %

    -53.1

    %

    -

     

     

    11

    19

    -41.0

    %

    -41.0

    %

    -

     

    Intl

     

    43

     

    58

    -24.2

    %

    -22.4

    %

    -1.8

    %

     

    203

    278

    -26.7

    %

    -23.9

    %

    -2.8

    %

    WW

     

    45

     

    62

    -26.1

    %

    -24.4

    %

    -1.7

    %

     

    214

    297

    -27.6

    %

    -25.0

    %

    -2.6

    %

     
     
     
     

    REPORTED SALES vs. PRIOR PERIOD ($MM)

     

     

    REPORTED SALES vs. PRIOR PERIOD ($MM)

    FOURTH QUARTER

     

     

    TWELVE MONTHS

     

     

     

     

    % Change

     

     

     

     

     

     

    % Change

    2024

     

    2023

     

    Reported

     

    Operational (1)

     

    Currency

     

     

    2024

     

    2023

     

    Reported

     

    Operational (1)

     

    Currency

    NEUROSCIENCE
    US

     

    1,148

     

    1,022

    12.3

    %

    12.3

    %

    -

     

     

    4,398

    4,065

    8.2

    %

    8.2

    %

    -

     

    Intl

     

    628

     

    780

    -19.6

    %

    -16.8

    %

    -2.8

    %

     

    2,718

    3,076

    -11.6

    %

    -7.8

    %

    -3.8

    %

    WW

     

    1,775

     

    1,801

    -1.5

    %

    -0.3

    %

    -1.2

    %

     

    7,115

    7,140

    -0.4

    %

    1.3

    %

    -1.7

    %

    CONCERTA / Methylphenidate
    US

     

    33

     

    39

    -12.8

    %

    -12.8

    %

    -

     

     

    134

    230

    -41.7

    %

    -41.7

    %

    -

     

    Intl

     

    125

     

    142

    -11.5

    %

    -7.7

    %

    -3.8

    %

     

    507

    554

    -8.4

    %

    -4.1

    %

    -4.3

    %

    WW

     

    159

     

    180

    -11.7

    %

    -8.8

    %

    -2.9

    %

     

    641

    783

    -18.1

    %

    -15.1

    %

    -3.0

    %

    INVEGA SUSTENNA / XEPLION /

    INVEGA TRINZA / TREVICTA
    US

     

    796

     

    733

    8.6

    %

    8.6

    %

    -

     

     

    3,125

    2,897

    7.9

    %

    7.9

    %

    -

     

    Intl

     

    267

     

    278

    -4.0

    %

    -1.8

    %

    -2.2

    %

     

    1,097

    1,218

    -9.9

    %

    -7.1

    %

    -2.8

    %

    WW

     

    1,063

     

    1,011

    5.1

    %

    5.7

    %

    -0.6

    %

     

    4,222

    4,115

    2.6

    %

    3.4

    %

    -0.8

    %

    SPRAVATO
    US

     

    269

     

    180

    50.1

    %

    50.1

    %

    -

     

     

    929

    589

    57.8

    %

    57.8

    %

    -

     

    Intl

     

    28

     

    26

    7.1

    %

    12.5

    %

    -5.4

    %

     

    148

    100

    48.2

    %

    51.2

    %

    -3.0

    %

    WW

     

    297

     

    206

    44.6

    %

    45.3

    %

    -0.7

    %

     

    1,077

    689

    56.4

    %

    56.8

    %

    -0.4

    %

    OTHER NEUROSCIENCE
    US

     

    49

     

    71

    -31.0

    %

    -31.0

    %

    -

     

     

    210

    349

    -39.8

    %

    -39.8

    %

    -

     

    Intl

     

    206

     

    334

    -38.1

    %

    -35.4

    %

    -2.7

    %

     

    965

    1,204

    -19.8

    %

    -15.1

    %

    -4.7

    %

    WW

     

    255

     

    404

    -36.9

    %

    -34.6

    %

    -2.3

    %

     

    1,175

    1,553

    -24.3

    %

    -20.7

    %

    -3.6

    %

    ONCOLOGY
    US

     

    3,019

     

    2,285

    32.2

    %

    32.2

    %

    -

     

     

    10,854

    8,462

    28.3

    %

    28.3

    %

    -

     

    Intl

     

    2,476

     

    2,334

    6.1

    %

    10.6

    %

    -4.5

    %

     

    9,926

    9,199

    7.9

    %

    12.1

    %

    -4.2

    %

    WW

     

    5,497

     

    4,618

    19.0

    %

    21.3

    %

    -2.3

    %

     

    20,781

    17,661

    17.7

    %

    19.8

    %

    -2.1

    %

    CARVYKTI
    US

     

    304

     

    145

    * *

    -

     

     

    869

    469

    85.2

    %

    85.2

    %

    -

     

    Intl

     

    31

     

    13

    * * *

     

    94

    30

    * * *
    WW

     

    334

     

    159

    * * *

     

    963

    500

    92.7

    %

    92.7

    %

    0.0

    %

    DARZALEX
    US

     

    1,799

     

    1,395

    28.9

    %

    28.9

    %

    -

     

     

    6,588

    5,277

    24.8

    %

    24.8

    %

    -

     

    Intl

     

    1,285

     

    1,155

    11.3

    %

    17.0

    %

    -5.7

    %

     

    5,082

    4,467

    13.8

    %

    19.1

    %

    -5.3

    %

    WW

     

    3,084

     

    2,550

    20.9

    %

    23.5

    %

    -2.6

    %

     

    11,670

    9,744

    19.8

    %

    22.2

    %

    -2.4

    %

    ERLEADA
    US

     

    342

     

    287

    19.0

    %

    19.0

    %

    -

     

     

    1,282

    1,065

    20.3

    %

    20.3

    %

    -

     

    Intl

     

    442

     

    361

    22.4

    %

    25.7

    %

    -3.3

    %

     

    1,717

    1,322

    29.8

    %

    32.9

    %

    -3.1

    %

    WW

     

    784

     

    647

    20.9

    %

    22.7

    %

    -1.8

    %

     

    2,999

    2,387

    25.6

    %

    27.3

    %

    -1.7

    %

    IMBRUVICA
    US

     

    250

     

    255

    -2.0

    %

    -2.0

    %

    -

     

     

    1,020

    1,051

    -3.0

    %

    -3.0

    %

    -

     

    Intl

     

    481

     

    533

    -9.6

    %

    -6.8

    %

    -2.8

    %

     

    2,018

    2,214

    -8.8

    %

    -6.3

    %

    -2.5

    %

    WW

     

    731

     

    788

    -7.2

    %

    -5.2

    %

    -2.0

    %

     

    3,038

    3,264

    -6.9

    %

    -5.2

    %

    -1.7

    %

    TECVAYLI
    US

     

    108

     

    102

    5.6

    %

    5.6

    %

    -

     

     

    418

    334

    25.3

    %

    25.3

    %

    -

     

    Intl

     

    38

     

    24

    59.9

    %

    71.6

    %

    -11.7

    %

     

    131

    61

    * * *
    WW

     

    146

     

    126

    15.8

    %

    18.0

    %

    -2.2

    %

     

    549

    395

    38.8

    %

    39.8

    %

    -1.0

    %

    ZYTIGA / abiraterone acetate
    US

     

    9

     

    9

    -7.3

    %

    -7.3

    %

    -

     

     

    34

    50

    -32.2

    %

    -32.2

    %

    -

     

    Intl

     

    127

     

    191

    -33.6

    %

    -30.7

    %

    -2.9

    %

     

    597

    837

    -28.6

    %

    -24.6

    %

    -4.0

    %

    WW

     

    135

     

    201

    -32.4

    %

    -29.6

    %

    -2.8

    %

     

    631

    887

    -28.8

    %

    -25.0

    %

    -3.8

    %

    OTHER ONCOLOGY
    US

     

    208

     

    90

    * *

    -

     

     

    643

    215

    * *

    -

     

    Intl

     

    74

     

    58

    25.5

    %

    30.6

    %

    -5.1

    %

     

    288

    269

    7.1

    %

    10.4

    %

    -3.3

    %

    WW

     

    282

     

    148

    90.4

    %

    92.4

    %

    -2.0

    %

     

    931

    484

    92.5

    %

    94.3

    %

    -1.8

    %

     
     
     

    REPORTED SALES vs. PRIOR PERIOD ($MM)

     

     

    REPORTED SALES vs. PRIOR PERIOD ($MM)

    FOURTH QUARTER

     

     

    TWELVE MONTHS

     

     

     

     

     

    % Change

     

     

     

     

     

     

    % Change

     

    2024

     

    2023

     

    Reported

     

    Operational (1)

     

    Currency

     

     

    2024

     

    2023

     

    Reported

     

    Operational (1)

     

    Currency

    PULMONARY HYPERTENSION
    US

     

    819

     

    733

    11.6

    %

    11.6

    %

    -

     

     

    3,143

    2,697

    16.5

    %

    16.5

    %

    -

     

    Intl

     

    274

     

    282

    -3.2

    %

    1.2

    %

    -4.4

    %

     

    1,140

    1,117

    2.0

    %

    8.2

    %

    -6.2

    %

    WW

     

    1,092

     

    1,017

    7.4

    %

    8.7

    %

    -1.3

    %

     

    4,282

    3,815

    12.3

    %

    14.1

    %

    -1.8

    %

    OPSUMIT
    US

     

    385

     

    368

    4.8

    %

    4.8

    %

    -

     

     

    1,520

    1,292

    17.7

    %

    17.7

    %

    -

     

    Intl

     

    160

     

    169

    -5.2

    %

    -2.5

    %

    -2.7

    %

     

    664

    681

    -2.4

    %

    1.1

    %

    -3.5

    %

    WW

     

    545

     

    536

    1.7

    %

    2.5

    %

    -0.8

    %

     

    2,184

    1,973

    10.7

    %

    11.9

    %

    -1.2

    %

    UPTRAVI
    US

     

    391

     

    348

    12.3

    %

    12.3

    %

    -

     

     

    1,511

    1,326

    13.9

    %

    13.9

    %

    -

     

    Intl

     

    75

     

    70

    5.7

    %

    11.2

    %

    -5.5

    %

     

    307

    255

    20.1

    %

    27.3

    %

    -7.2

    %

    WW

     

    465

     

    419

    11.2

    %

    12.1

    %

    -0.9

    %

     

    1,817

    1,582

    14.9

    %

    16.1

    %

    -1.2

    %

    OTHER PULMONARY HYPERTENSION
    US

     

    42

     

    18

    * *

    -

     

     

    112

    79

    41.8

    %

    41.8

    %

    -

     

    Intl

     

    40

     

    45

    -10.0

    %

    -0.4

    %

    -9.6

    %

     

    169

    182

    -6.9

    %

    8.2

    %

    -15.1

    %

    WW

     

    82

     

    61

    32.3

    %

    39.3

    %

    -7.0

    %

     

    281

    260

    7.9

    %

    18.3

    %

    -10.4

    %

    CARDIOVASCULAR / METABOLISM / OTHER
    US

     

    805

     

    652

    23.3

    %

    23.3

    %

    -

     

     

    2,866

    2,906

    -1.4

    %

    -1.4

    %

    -

     

    Intl

     

    153

     

    185

    -17.6

    %

    -15.1

    %

    -2.5

    %

     

    696

    765

    -9.1

    %

    -7.1

    %

    -2.0

    %

    WW

     

    957

     

    837

    14.3

    %

    14.8

    %

    -0.5

    %

     

    3,562

    3,671

    -3.0

    %

    -2.6

    %

    -0.4

    %

    XARELTO
    US

     

    676

     

    525

    28.5

    %

    28.5

    %

    -

     

     

    2,373

    2,365

    0.3

    %

    0.3

    %

    -

     

    Intl

     

    -

     

    -

    -

     

    -

     

    -

     

     

    -

    -

    -

     

    -

     

    -

     

    WW

     

    676

     

    525

    28.5

    %

    28.5

    %

    -

     

     

    2,373

    2,365

    0.3

    %

    0.3

    %

    -

     

    OTHER
    US

     

    130

     

    127

    1.5

    %

    1.5

    %

    -

     

     

    494

    541

    -8.8

    %

    -8.8

    %

    -

     

    Intl

     

    153

     

    185

    -17.6

    %

    -15.1

    %

    -2.5

    %

     

    696

    765

    -9.1

    %

    -7.1

    %

    -2.0

    %

    WW

     

    281

     

    312

    -9.8

    %

    -8.3

    %

    -1.5

    %

     

    1,189

    1,306

    -8.9

    %

    -7.8

    %

    -1.1

    %

     
    TOTAL INNOVATIVE MEDICINE
    US

     

    8,977

     

    8,079

    11.1

    %

    11.1

    %

    -

     

     

    33,970

    31,169

    9.0

    %

    9.0

    %

    -

     

    Intl

     

    5,355

     

    5,643

    -5.1

    %

    -1.0

    %

    -4.1

    %

     

    22,994

    23,590

    -2.5

    %

    1.3

    %

    -3.8

    %

    WW

    $

    14,332

    $

    13,722

    4.4

    %

    6.1

    %

    -1.7

    %

    $

    56,964

    54,759

    4.0

    %

    5.7

    %

    -1.7

    %

     
     
    See footnotes at end of schedule
     
     
     

    REPORTED SALES vs. PRIOR PERIOD ($MM)

     

     

    REPORTED SALES vs. PRIOR PERIOD ($MM)

    FOURTH QUARTER

     

     

    TWELVE MONTHS

     

     

     

     

     

    % Change

     

     

     

     

     

     

    % Change

    MEDTECH SEGMENT (2)

     

    2024

     

    2023

     

    Reported

     

    Operational (1)

     

    Currency

     

     

    2024

     

    2023

     

    Reported

     

    Operational (1)

     

    Currency

     
    CARDIOVASCULAR (4)
    US

    $

    1,221

     

    971

    25.8

    %

    25.8

    %

    -

     

    $

    4,513

    3,633

    24.2

    %

    24.2

    %

    -

     

    Intl

     

    841

     

    698

    20.6

    %

    22.0

    %

    -1.4

    %

     

    3,194

    2,717

    17.6

    %

    20.9

    %

    -3.3

    %

    WW

     

    2,062

     

    1,669

    23.6

    %

    24.2

    %

    -0.6

    %

     

    7,707

    6,350

    21.4

    %

    22.8

    %

    -1.4

    %

    ELECTROPHYSIOLOGY
    US

     

    681

     

    667

    2.1

    %

    2.1

    %

    -

     

     

    2,738

    2,458

    11.4

    %

    11.4

    %

    -

     

    Intl

     

    640

     

    572

    11.7

    %

    13.3

    %

    -1.6

    %

     

    2,529

    2,230

    13.4

    %

    17.0

    %

    -3.6

    %

    WW

     

    1,321

     

    1,239

    6.6

    %

    7.3

    %

    -0.7

    %

     

    5,267

    4,688

    12.3

    %

    14.0

    %

    -1.7

    %

    ABIOMED
    US

     

    308

     

    276

    11.3

    %

    11.3

    %

    -

     

     

    1,213

    1,066

    13.7

    %

    13.7

    %

    -

     

    Intl

     

    77

     

    64

    19.8

    %

    21.1

    %

    -1.3

    %

     

    284

    240

    18.2

    %

    20.3

    %

    -2.1

    %

    WW

     

    384

     

    340

    12.9

    %

    13.2

    %

    -0.3

    %

     

    1,496

    1,306

    14.5

    %

    14.9

    %

    -0.4

    %

    SHOCKWAVE (5)
    US

     

    202

     

    -

    * *

    -

     

     

    442

    -

    * *

    -

     

    Intl

     

    56

     

    -

    * *

    -

     

     

    122

    -

    * *

    -

     

    WW

     

    258

     

    -

    * *

    -

     

     

    564

    -

    * *

    -

     

    OTHER CARDIOVASCULAR (4)
    US

     

    31

     

    28

    11.1

    %

    11.1

    %

    -

     

     

    120

    109

    10.7

    %

    10.7

    %

    -

     

    Intl

     

    68

     

    61

    12.1

    %

    12.3

    %

    -0.2

    %

     

    260

    247

    5.3

    %

    7.3

    %

    -2.0

    %

    WW

     

    99

     

    89

    11.8

    %

    12.0

    %

    -0.2

    %

     

    380

    356

    6.9

    %

    8.4

    %

    -1.5

    %

    ORTHOPAEDICS
    US

     

    1,460

     

    1,425

    2.4

    %

    2.4

    %

    -

     

     

    5,689

    5,525

    3.0

    %

    3.0

    %

    -

     

    Intl

     

    856

     

    843

    1.6

    %

    2.5

    %

    -0.9

    %

     

    3,470

    3,417

    1.5

    %

    3.0

    %

    -1.5

    %

    WW

     

    2,315

     

    2,268

    2.1

    %

    2.5

    %

    -0.4

    %

     

    9,158

    8,942

    2.4

    %

    3.0

    %

    -0.6

    %

    HIPS
    US

     

    272

     

    266

    2.5

    %

    2.5

    %

    -

     

     

    1,057

    996

    6.2

    %

    6.2

    %

    -

     

    Intl

     

    146

     

    132

    10.6

    %

    11.7

    %

    -1.1

    %

     

    581

    564

    3.0

    %

    4.6

    %

    -1.6

    %

    WW

     

    418

     

    398

    5.2

    %

    5.6

    %

    -0.4

    %

     

    1,638

    1,560

    5.0

    %

    5.6

    %

    -0.6

    %

    KNEES
    US

     

    238

     

    242

    -1.5

    %

    -1.5

    %

    -

     

     

    922

    896

    2.9

    %

    2.9

    %

    -

     

    Intl

     

    160

     

    144

    10.7

    %

    11.3

    %

    -0.6

    %

     

    623

    559

    11.3

    %

    12.4

    %

    -1.1

    %

    WW

     

    398

     

    387

    3.1

    %

    3.3

    %

    -0.2

    %

     

    1,545

    1,456

    6.1

    %

    6.5

    %

    -0.4

    %

    TRAUMA
    US

     

    514

     

    487

    5.5

    %

    5.5

    %

    -

     

     

    2,013

    1,949

    3.3

    %

    3.3

    %

    -

     

    Intl

     

    250

     

    255

    -1.9

    %

    -0.5

    %

    -1.4

    %

     

    1,036

    1,030

    0.6

    %

    2.1

    %

    -1.5

    %

    WW

     

    764

     

    741

    3.0

    %

    3.5

    %

    -0.5

    %

     

    3,049

    2,979

    2.3

    %

    2.9

    %

    -0.6

    %

    SPINE, SPORTS & OTHER
    US

     

    434

     

    430

    1.1

    %

    1.1

    %

    -

     

     

    1,696

    1,684

    0.7

    %

    0.7

    %

    -

     

    Intl

     

    300

     

    311

    -3.6

    %

    -2.9

    %

    -0.7

    %

     

    1,230

    1,263

    -2.6

    %

    -1.2

    %

    -1.4

    %

    WW

     

    735

     

    742

    -0.9

    %

    -0.6

    %

    -0.3

    %

     

    2,926

    2,947

    -0.7

    %

    -0.1

    %

    -0.6

    %

     
     
     
     

    REPORTED SALES vs. PRIOR PERIOD ($MM)

     

     

    REPORTED SALES vs. PRIOR PERIOD ($MM)

    FOURTH QUARTER

     

     

    TWELVE MONTHS

     

     

     

     

     

    % Change

     

     

     

     

     

     

    % Change

     

    2024

     

    2023

     

    Reported

     

    Operational (1)

     

    Currency

     

     

    2024

     

    2023

     

    Reported

     

    Operational (1)

     

    Currency

    SURGERY
    US

     

    1,038

     

    1,047

    -0.9

    %

    -0.9

    %

    -

     

     

    4,003

    4,031

    -0.7

    %

    -0.7

    %

    -

     

    Intl

     

    1,469

     

    1,484

    -1.0

    %

    1.4

    %

    -2.4

    %

     

    5,842

    6,006

    -2.7

    %

    0.6

    %

    -3.3

    %

    WW

     

    2,507

     

    2,530

    -0.9

    %

    0.4

    %

    -1.3

    %

     

    9,845

    10,037

    -1.9

    %

    0.1

    %

    -2.0

    %

    ADVANCED
    US

     

    478

     

    468

    2.0

    %

    2.0

    %

    -

     

     

    1,838

    1,833

    0.2

    %

    0.2

    %

    -

     

    Intl

     

    673

     

    698

    -3.6

    %

    -1.6

    %

    -2.0

    %

     

    2,650

    2,837

    -6.6

    %

    -3.5

    %

    -3.1

    %

    WW

     

    1,151

     

    1,167

    -1.4

    %

    -0.1

    %

    -1.3

    %

     

    4,488

    4,671

    -3.9

    %

    -2.0

    %

    -1.9

    %

    GENERAL
    US

     

    560

     

    579

    -3.1

    %

    -3.1

    %

    -

     

     

    2,165

    2,198

    -1.5

    %

    -1.5

    %

    -

     

    Intl

     

    795

     

    785

    1.4

    %

    4.0

    %

    -2.6

    %

     

    3,192

    3,168

    0.8

    %

    4.3

    %

    -3.5

    %

    WW

     

    1,357

     

    1,364

    -0.5

    %

    1.0

    %

    -1.5

    %

     

    5,358

    5,366

    -0.2

    %

    2.0

    %

    -2.2

    %

    VISION
    US

     

    509

     

    487

    4.5

    %

    4.5

    %

    -

     

     

    2,128

    2,086

    2.0

    %

    2.0

    %

    -

     

    Intl

     

    794

     

    721

    10.2

    %

    12.2

    %

    -2.0

    %

     

    3,018

    2,986

    1.1

    %

    3.7

    %

    -2.6

    %

    WW

     

    1,303

     

    1,208

    7.9

    %

    9.1

    %

    -1.2

    %

     

    5,146

    5,072

    1.5

    %

    3.0

    %

    -1.5

    %

    CONTACT LENSES / OTHER
    US

     

    396

     

    374

    6.0

    %

    6.0

    %

    -

     

     

    1,684

    1,626

    3.6

    %

    3.6

    %

    -

     

    Intl

     

    541

     

    508

    6.4

    %

    8.5

    %

    -2.1

    %

     

    2,049

    2,076

    -1.3

    %

    1.8

    %

    -3.1

    %

    WW

     

    937

     

    882

    6.3

    %

    7.4

    %

    -1.1

    %

     

    3,733

    3,702

    0.8

    %

    2.6

    %

    -1.8

    %

    SURGICAL
    US

     

    113

     

    114

    -0.4

    %

    -0.4

    %

    -

     

     

    444

    460

    -3.4

    %

    -3.4

    %

    -

     

    Intl

     

    252

     

    212

    19.3

    %

    21.1

    %

    -1.8

    %

     

    969

    910

    6.5

    %

    8.2

    %

    -1.7

    %

    WW

     

    365

     

    326

    12.4

    %

    13.6

    %

    -1.2

    %

     

    1,413

    1,370

    3.2

    %

    4.3

    %

    -1.1

    %

     
    TOTAL MEDTECH
    US

     

    4,227

     

    3,930

    7.6

    %

    7.6

    %

    -

     

     

    16,332

    15,275

    6.9

    %

    6.9

    %

    -

     

    Intl

     

    3,961

     

    3,743

    5.8

    %

    7.6

    %

    -1.8

    %

     

    15,525

    15,125

    2.6

    %

    5.4

    %

    -2.8

    %

    WW

    $

    8,188

    $

    7,673

    6.7

    %

    7.6

    %

    -0.9

    %

    $

    31,857

    30,400

    4.8

    %

    6.2

    %

    -1.4

    %

     
     
    Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely
     
    * Percentage greater than 100% or not meaningful
    (1) Operational growth excludes the effect of translational currency
    (2) Unaudited
    (3) Reported as U.S. sales
    (4) Previously referred to as Interventional Solutions
    (5) Acquired on May 31, 2024
    Supplemental Sales Information (Unaudited)
    (Dollars in Millions)
     

    FOURTH QUARTER

     

    TWELVE MONTHS

     

     

     

     

    Percent Change

     

     

     

     

     

     

    Percent Change

     

     

    2024

     

    2023

     

    Total

     

    Operations

     

    Currency

     

     

    2024

     

    2023

     

    Total

     

    Operations

     

    Currency

     
    Innovative Medicine
    U.S.

    $

    8,977

    8,079

    11.1

     

    11.1

     

    -

     

    $

    33,970

    31,169

    9.0

     

    9.0

     

    -

     

    International

     

    5,355

    5,643

    (5.1

    )

    (1.0

    )

    (4.1

    )

     

    22,994

    23,590

    (2.5

    )

    1.3

     

    (3.8

    )

    Worldwide

     

    14,332

    13,722

    4.4

     

    6.1

     

    (1.7

    )

     

    56,964

    54,759

    4.0

     

    5.7

     

    (1.7

    )

     
    COVID-19 Vaccine
    U.S.

     

    -

    -

    -

     

    -

     

    -

     

     

    -

    -

    -

     

    -

     

    -

     

    International

     

    -

    44

    * * *

     

    198

    1,117

    (82.4

    )

    (82.4

    )

    0.0

     

    Worldwide

     

    -

    44

    * * *

     

    198

    1,117

    (82.4

    )

    (82.4

    )

    0.0

     

     
    Innovative Medicine excluding COVID-19 Vaccine
    U.S.

     

    8,977

    8,079

    11.1

     

    11.1

     

    -

     

     

    33,970

    31,169

    9.0

     

    9.0

     

    -

     

    International

     

    5,355

    5,599

    (4.4

    )

    (0.3

    )

    (4.1

    )

     

    22,796

    22,473

    1.4

     

    5.5

     

    (4.1

    )

    Worldwide

     

    14,332

    13,678

    4.8

     

    6.5

     

    (1.7

    )

     

    56,766

    53,642

    5.8

     

    7.5

     

    (1.7

    )

     
    Worldwide
    U.S.

     

    13,204

    12,009

    10.0

     

    10.0

     

    -

     

     

    50,302

    46,444

    8.3

     

    8.3

     

    -

     

    International

     

    9,316

    9,386

    (0.7

    )

    2.5

     

    (3.2

    )

     

    38,519

    38,715

    (0.5

    )

    2.9

     

    (3.4

    )

    Worldwide

     

    22,520

    21,395

    5.3

     

    6.7

     

    (1.4

    )

     

    88,821

    85,159

    4.3

     

    5.9

     

    (1.6

    )

     
    COVID-19 Vaccine
    U.S.

     

    -

    -

    -

     

    -

     

    -

     

     

    -

    -

    -

     

    -

     

    -

     

    International

     

    -

    44

    *

     

     

    *

     

     

    *

     

    198

    1,117

    (82.4

    )

    (82.4

    )

    0.0

     

    Worldwide

     

    -

    44

    *

     

     

    *

     

     

    *

     

    198

    1,117

    (82.4

    )

    (82.4

    )

    0.0

     

     
    Worldwide
    U.S.

     

    13,204

    12,009

    10.0

     

    10.0

     

    -

     

     

    50,302

    46,444

    8.3

     

    8.3

     

    -

     

    International

     

    9,316

    9,342

    (0.3

    )

    2.9

     

    (3.2

    )

     

    38,321

    37,598

    1.9

     

    5.5

     

    (3.6

    )

    Worldwide excluding COVID-19 Vaccine

    $

    22,520

    21,351

    5.5

     

    6.9

     

    (1.4

    )

    $

    88,623

    84,042

    5.5

     

    7.0

     

    (1.5

    )

     
    Europe

    $

    4,921

    4,962

    (0.8

    )

    (0.2

    )

    (0.6

    )

    $

    20,212

    20,410

    (1.0

    )

    (0.6

    )

    (0.4

    )

    Europe COVID-19 Vaccine Sales

     

    -

    44

    *

     

     

    *

     

     

    *

     

    198

    1,117

    (82.4

    )

    (82.4

    )

    0.0

     

    Europe excluding COVID-19 Vaccine Sales

    $

    4,921

    4,918

    0.1

     

    0.7

     

    (0.6

    )

    $

    20,014

    19,293

    3.7

     

    4.1

     

    (0.4

    )

     
    * Percentage greater than 100% or not meaningful
    Johnson & Johnson and Subsidiaries
    Reconciliation of Non-GAAP Financial Measures
    Q4 QTD - Income Before Tax* and Research & Development Expense by Segment
    Dollars in Millions
     

    Innovative Medicine

     

    MedTech

     

    Unallocated

     

     

    Worldwide Total

    2024

    2023

    2024

    2023

     

    2024

    2023

     

     

    2024

    2023

     
    Reported Income Before Tax by Segment From Continuing Operations $

    4,009

     

    4,238

     

    72

     

    404

     

    (194

    )

    184

     

    3,887

     

    4,826

     

    % to Sales

    28.0

    %

    30.9

    %

    0.9

    %

    5.3

    %

    -0.9

    %

    0.9

    %

    17.3

    %

    22.6

    %

     
    Intangible asset amortization expense

    685

     

    747

     

    486

     

    401

     

    -

     

    -

     

    1,171

     

    1,148

     

     
    In-process research and development impairments

    17

     

    -

     

    -

     

    58

     

    -

     

    -

     

    17

     

    58

     

     
    Litigation related

    (41

    )

    17

     

    (29

    )

    149

     

    54

     

    -

     

    (16

    )

    166

     

     
    Loss/(gain) on securities

    (50

    )

    (112

    )

    (18

    )

    (59

    )

    -

     

    (264

    )

    (68

    )

    (435

    )

     
    Restructuring related

    2

     

    55

     

    60

     

    84

     

    -

     

    -

     

    62

     

    139

     

     
    Acquisition, integration and divestiture related

    12

     

    175

     

    268

     

    62

     

    18

     

    -

     

    298

     

    237

     

     
    Medical Device Regulation

    -

     

    -

     

    47

     

    88

     

    -

     

    -

     

    47

     

    88

     

     
    COVID-19 Vaccine related costs

    23

     

    10

     

    -

     

    -

     

    -

     

    -

     

    23

     

    10

     

     
    Adjusted Income Before Tax by Segment From Continuing Operations $

    4,657

     

    5,130

     

    886

     

    1,187

     

    (122

    )

    (80

    )

    5,421

     

    6,237

     

    % to Sales

    32.5

    %

    37.4

    %

    10.8

    %

    15.5

    %

    -0.5

    %

    -0.4

    %

    24.1

    %

    29.2

    %

     
    *Estimated as of 1/22/2025
     
    As Reported Research and development expense** $

    3,698

     

    3,357

     

    1,600

     

    1,123

     

    5,298

     

    4,480

     

    % to Sales

    25.8

    %

    24.5

    %

    19.5

    %

    14.6

    %

    23.5

    %

    20.9

    %

     
    **Includes the following Acquired IPR&D:
    Laminar - Q4 2023

    390

     

    390

     

    V-Wave - Q4 2024

    540

     

    540

     

    Total

    540

     

    390

     

    540

     

    390

     

     
    Johnson & Johnson and Subsidiaries
    Reconciliation of Non-GAAP Financial Measures
    Q4 YTD - Income Before Tax* and Research & Development Expense by Segment
    Dollars in Millions
     

    Innovative Medicine

     

    MedTech

     

    Unallocated

     

     

    Worldwide Total

    2024

     

    2023

     

    2024

     

    2023

     

    2024

     

    2023

     

     

    2024

     

    2023

     
    Reported Income Before Tax by Segment From Continuing Operations $

    18,919

     

    18,246

     

    3,740

     

    4,669

     

    (5,972

    )

    (7,853

    )

    16,687

     

    15,062

     

    % to Sales

    33.2

    %

    33.3

    %

    11.7

    %

    15.4

    %

    -6.7

    %

    -9.2

    %

    18.8

    %

    17.7

    %

     
    Intangible asset amortization expense

    2,772

     

    2,983

     

    1,754

     

    1,549

     

    -

     

    -

     

    4,526

     

    4,532

     

     
    In-process research and development impairments

    211

     

    206

     

    -

     

    107

     

    -

     

    -

     

    211

     

    313

     

     
    Litigation related

    358

     

    (108

    )

    (14

    )

    190

     

    5,106

     

    7,070

     

    5,450

     

    7,152

     

     
    Loss/(gain) on securities

    (76

    )

    362

     

    30

     

    (102

    )

    352

     

    381

     

    306

     

    641

     

     
    Restructuring related

    102

     

    479

     

    167

     

    319

     

    -

     

    -

     

    269

     

    798

     

     
    Acquisition, integration and divestiture related

    66

     

    175

     

    1,015

     

    164

     

    145

     

    -

     

    1,226

     

    339

     

     
    Medical Device Regulation

    -

     

    -

     

    204

     

    311

     

    -

     

    -

     

    204

     

    311

     

     
    COVID-19 Vaccine related costs

    100

     

    663

     

    -

     

    -

     

    -

     

    -

     

    100

     

    663

     

     
    Adjusted Income Before Tax by Segment From Continuing Operations $

    22,452

     

    23,006

     

    6,896

     

    7,207

     

    (369

    )

    (402

    )

    28,979

     

    29,811

     

    % to Sales

    39.4

    %

    42.0

    %

    21.6

    %

    23.7

    %

    -0.4

    %

    -0.5

    %

    32.6

    %

    35.0

    %

     
    *Estimated as of 1/22/2025
     
    As Reported Research and development expense** $

    13,529

     

    11,963

     

    3,703

     

    3,122

     

    17,232

     

    15,085

     

    % to Sales

    23.8

    %

    21.8

    %

    11.6

    %

    10.3

    %

    19.4

    %

    17.7

    %

     
    **Includes the following Acquired IPR&D:
    Laminar - Q4 2023

    390

     

    390

     

    Yellow Jersey (NM26 bispecific antibody) - Q3 2024

    1,250

     

    1,250

     

    V-Wave -Q4 2024

    540

     

    540

     

    Total

    1,250

     

    540

     

    390

     

    1,790

     

    390

     

    Johnson & Johnson and Subsidiaries
    GAAP to Non-GAAP Reconciliation
    $ in Millions
     
    Quarter to Date
     
    In-process

    research and

    development

    impairments
    Acquisition, integration

    and divestiture related
    (Loss)/gain on

    securities
    COVID-19

    Vaccine Related

    Costs
    Tax legislation

    and other tax

    related
    Fourth Quarter Dec. 29, 2024

    GAAP
    Intangible asset

    amortization
    Litigation

    related
    Restructuring

    related
    Medical Device

    Regulation
    Fourth Quarter

    Dec. 29, 2024

    Non-GAAP
    Cost of products sold

    $

    7,128

     

    (1,162

    )

    (20

    )

    (153

    )

    (18

    )

    -

     

    -

     

    5,775

     

    Selling, marketing and admin expenses

     

    6,453

     

    (4

    )

    6,449

     

    Research and development expense

     

    5,298

     

    -

     

    (25

    )

    (6

    )

    5,267

     

    Other (Income) / Expense

     

    (161

    )

    (9

    )

    16

     

    -

     

    (145

    )

    68

     

    (17

    )

    (248

    )

    In-process research and development impairments

     

    17

     

    (17

    )

    -

     

    -

     

    Restructuring

     

    42

     

    (42

    )

    -

     

    Provision for taxes on income

     

    456

     

    171

     

    (158

    )

    4

     

    3

     

    80

     

    (34

    )

    9

     

    5

     

    (61

    )

    475

     

    Net Earnings from Continuing Operations

     

    3,431

     

    1,000

     

    142

     

    13

     

    59

     

    218

     

    (34

    )

    38

     

    18

     

    61

     

    4,946

     

     
     
    In-process

    research and

    development

    impairments
    Acquisition, integration

    and divestiture related
    (Loss)/gain on

    securities
    COVID-19

    Vaccine Related

    Costs
    Tax legislation

    and other tax

    related
    Fourth Quarter

    Dec. 31, 2023

    GAAP
    Intangible asset

    amortization
    Litigation

    related
    Restructuring

    related
    Medical Device

    Regulation
    Fourth Quarter

    Dec. 31, 2023

    Non-GAAP
    Cost of products sold

    $

    6,798

     

    (1,131

    )

    (83

    )

    (42

    )

    (12

    )

    -

     

    5,530

     

    Selling, marketing and admin expenses

     

    5,810

     

    (8

    )

    5,802

     

    Research and development expense

     

    4,480

     

    (16

    )

    (38

    )

    (1

    )

    4,425

     

    Other (Income) / Expense

     

    (421

    )

    (17

    )

    (166

    )

    -

     

    (221

    )

    435

     

    3

     

    (387

    )

    In-process research and development impairments

     

    58

     

    (58

    )

    -

     

    Restructuring

     

    56

     

    (56

    )

    -

     

    Provision for taxes on income

     

    694

     

    175

     

    (134

    )

    13

     

    16

     

    30

     

    (191

    )

    16

     

    -

     

    56

     

    675

     

    Net Earnings from Continuing Operations

     

    4,132

     

    973

     

    300

     

    45

     

    123

     

    207

     

    (244

    )

    72

     

    10

     

    (56

    )

    5,562

     

     
    Year to Date
     
    In-process

    research and

    development

    impairments
    Acquisition, integration

    and divestiture related
    (Loss)/gain on

    securities
    COVID-19

    Vaccine Related

    Costs
    Tax legislation

    and other tax

    related
    Twelve Months Dec. 29, 2024

    GAAP
    Intangible asset

    amortization
    Litigation

    related
    Restructuring

    related
    Medical Device

    Regulation
    Twelve Months

    Dec. 29, 2024

    Non-GAAP
    Cost of products sold

    $

    27,471

     

    (4,517

    )

    (35

    )

    (359

    )

    (84

    )

    (8

    )

    22,468

     

    Selling, marketing and admin expenses

     

    22,869

     

    (16

    )

    -

     

    22,853

     

    Research and development expense

     

    17,232

     

    (69

    )

    (104

    )

    (25

    )

    17,034

     

    Other (Income) / Expense

     

    4,694

     

    (9

    )

    (5,450

    )

    -

     

    (798

    )

    (306

    )

    (67

    )

    (1,936

    )

    In-process research and development impairments

     

    211

     

    (211

    )

    -

     

    -

     

    -

     

    -

     

    -

     

    Restructuring

     

    234

     

    (234

    )

    -

     

    Provision for taxes on income

     

    2,621

     

    644

     

    1,066

     

    47

     

    45

     

    302

     

    (29

    )

    38

     

    22

     

    (19

    )

    4,737

     

    Net Earnings from Continuing Operations

     

    14,066

     

    3,882

     

    4,384

     

    164

     

    224

     

    924

     

    335

     

    166

     

    78

     

    19

     

    24,242

     

     
     
    In-process

    research and

    development

    impairments
    Acquisition, integration

    and divestiture related
    (Loss)/gain on

    securities
    COVID-19

    Vaccine Related

    Costs
    Tax legislation

    and other tax

    related
    Twelve Months

    Dec. 31, 2023

    GAAP
    Intangible asset

    amortization
    Litigation

    related
    Restructuring

    related
    Medical Device

    Regulation
    Twelve Months

    Dec. 31, 2023

    Non-GAAP
    Cost of products sold

    $

    26,553

     

    (4,511

    )

    (309

    )

    (133

    )

    (189

    )

    21,411

     

    Selling, marketing and admin expenses

     

    21,512

     

    (29

    )

    21,483

     

    Research and development expense

     

    15,085

     

    (32

    )

    (149

    )

    (99

    )

    14,805

     

    Other (Income) / Expense

     

    6,634

     

    (21

    )

    (7,152

    )

    -

     

    (307

    )

    (641

    )

    (375

    )

    (1,862

    )

    In-process research and development impairments

     

    313

     

    (313

    )

    -

     

    -

     

    Restructuring

     

    489

     

    (489

    )

    -

     

    Provision for taxes on income

     

    1,736

     

    707

     

    1,505

     

    70

     

    157

     

    52

     

    (9

    )

    57

     

    155

     

    (28

    )

    4,402

     

    Net Earnings from Continuing Operations

     

    13,326

     

    3,825

     

    5,647

     

    243

     

    641

     

    287

     

    650

     

    254

     

    508

     

    28

     

    25,409

     

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250121770243/en/

    Media contact:

    [email protected]

    Investor contact:

    [email protected]

    Get the next $JNJ alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $JNJ

    DatePrice TargetRatingAnalyst
    5/13/2025$153.00Outperform → Market Perform
    Leerink Partners
    12/10/2024$166.00Neutral
    BofA Securities
    11/15/2024$190.00Outperform
    Wolfe Research
    7/23/2024$160.00 → $150.00Outperform → Neutral
    Daiwa Securities
    5/30/2024$160.00Neutral
    Goldman
    4/18/2024$170.00Hold → Buy
    HSBC Securities
    12/13/2023$170.00 → $163.00Overweight → Equal Weight
    Wells Fargo
    12/1/2023$167.00 → $180.00Neutral → Buy
    UBS
    More analyst ratings

    $JNJ
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • July 21, 2023 - FDA Roundup: July 21, 2023

      For Immediate Release: July 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA Center for Tobacco Products (CTP) announced that the center will host a virtual listening session on Aug. 22, 2023. During this listening session, CTP is requesting feedback on the development of a new 5-year strategic plan for the center, includin

      7/21/23 4:02:23 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • May 5, 2022 - Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals

      For Immediate Release: May 05, 2022 Today, the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not

      5/5/22 4:51:11 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • August 18, 2021 - Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster Shots

      For Immediate Release: August 18, 2021 Today, public health and medical experts from the U.S. Department of Health and Human Services (HHS) released the following statement on the Administration’s plan for COVID-19 booster shots for the American people. The statement is attributable to Dr. Rochelle Walensky, Director of the Centers for Disease Control and Prevention (CDC); Dr. Janet Woodcock, Acting Commissione

      8/18/21 1:06:11 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Johnson & Johnson downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded Johnson & Johnson from Outperform to Market Perform and set a new price target of $153.00

      5/13/25 8:56:13 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BofA Securities resumed coverage on Johnson & Johnson with a new price target

      BofA Securities resumed coverage of Johnson & Johnson with a rating of Neutral and set a new price target of $166.00

      12/10/24 8:28:42 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wolfe Research initiated coverage on Johnson & Johnson with a new price target

      Wolfe Research initiated coverage of Johnson & Johnson with a rating of Outperform and set a new price target of $190.00

      11/15/24 8:10:35 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Hewson Marillyn A

      4 - JOHNSON & JOHNSON (0000200406) (Issuer)

      6/12/25 4:32:25 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Woods Eugene A.

      4 - JOHNSON & JOHNSON (0000200406) (Issuer)

      6/12/25 4:30:37 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, Innovative Medicine, R&D Reed John C converted options into 25,255 shares and covered exercise/tax liability with 11,002 shares, increasing direct ownership by 92% to 29,795 units (SEC Form 4)

      4 - JOHNSON & JOHNSON (0000200406) (Issuer)

      5/5/25 5:10:14 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Weinberger Mark A bought $147,220 worth of shares (1,000 units at $147.22) (SEC Form 4)

      4 - JOHNSON & JOHNSON (0000200406) (Issuer)

      12/12/24 5:27:36 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    Financials

    Live finance-specific insights

    See more
    • Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

      Johnson & Johnson (NYSE:JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, July 16th to review second-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Darren Snellgrove, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson's executive team. Investors and other interested parties can access the webcast/conference call in the following ways: The webcast and presentation material are accessible at Johnson & Johnson's website www.investor.jnj.com. A replay o

      5/28/25 4:43:00 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Johnson & Johnson Announces 63rd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.8%

      Johnson & Johnson (NYSE:JNJ) today announced that its Board of Directors has declared a 4.8% increase in the quarterly dividend, from $1.24 per share to $1.30 per share, marking the 63rd year of consecutive increases. At the new rate, the indicated dividend on an annual basis is $5.20 per share compared to the previous rate of $4.96 per share. The next quarterly dividend is payable on June 10, 2025 to shareholders of record at the close of business on May 27, 2025. The ex-dividend date is May 27, 2025. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, trea

      4/15/25 6:25:00 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Johnson & Johnson Reports Q1 2025 Results

      2025 First-Quarter reported sales growth of 2.4% to $21.9 Billion with operational growth of 4.2%* and adjusted operational growth of 3.3%* 2025 First-Quarter earnings per share (EPS) increased to $4.54 which includes the reversal of special charges and adjusted EPS increased to $2.77 or 2.2%* Significant new product pipeline progress including approval of TREMFYA in Crohn's disease, data for RYBREVANT/LAZCLUZE overall survival in non-small cell lung cancer and icotrokinra in plaque psoriasis, and initiation of the clinical trial for a general surgery robotic system, OTTAVA Company increases Full-Year 2025 operational sales2,5 guidance to reflect the addition of CAPLYTA following the

      4/15/25 6:20:00 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    Leadership Updates

    Live Leadership Updates

    See more
    • Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors

      Johnson & Johnson (NYSE:JNJ) announced today that Daniel Pinto, President, JPMorganChase, has been elected to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250610707025/en/ "We are thrilled to have Daniel join Johnson & Johnson's Board of Directors," said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "He is an exceptional leader with deep financial expertise and understanding of global capital markets. Daniel's unique perspective and wealth of experience will be a tremendous asset to Johnson & Johnson as we continue to invest in and advance the next generation of healthcare inno

      6/10/25 4:51:00 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan

      WARREN, N.J., March 25, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech company leveraging AI-driven immunotherapy drug discovery, today announced the appointment of David E. Banko, CPA, a leading expert with three decades of industry experience in market access and health policy, to its leadership team as Global Head of Government Affairs and Patient Access. In this critical role, Mr. Banko will spearhead market access strategies in collaboration with R&D across Tevogen's growing product portfolio in oncology, virology, neurology, and rheumatology to advance and support commercial readines

      3/25/25 1:11:06 PM ET
      $JNJ
      $TVGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Johnson & Johnson Announces Darren Snellgrove as Vice President, Investor Relations

      Jessica Moore Appointed Group Chief Financial Officer, Johnson & Johnson, Innovative Medicine Johnson & Johnson (NYSE:JNJ) (the "Company") today announced the appointment of Darren Snellgrove to Vice President, Investor Relations. Jessica Moore, who has served as Vice President, Investor Relations since 2021, will assume the role of Group Chief Financial Officer, Johnson & Johnson, Innovative Medicine. The new appointments are effective May 1, 2025, and Mr. Snellgrove as well as Ms. Moore, will continue to report to Johnson & Johnson's Executive Vice President and Chief Financial Officer, Joseph Wolk. "Today's announcement reflects the deep bench of talent within Johnson & Johnson as well

      3/4/25 4:15:00 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Johnson & Johnson

      SC 13G - JOHNSON & JOHNSON (0000200406) (Filed by)

      4/10/24 5:12:55 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Johnson & Johnson (Amendment)

      SC 13G/A - JOHNSON & JOHNSON (0000200406) (Subject)

      2/13/24 5:07:58 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Johnson & Johnson (Amendment)

      SC 13G/A - JOHNSON & JOHNSON (0000200406) (Subject)

      1/30/24 12:46:49 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    SEC Filings

    See more
    • SEC Form 11-K filed by Johnson & Johnson

      11-K - JOHNSON & JOHNSON (0000200406) (Filer)

      6/23/25 9:42:57 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 11-K filed by Johnson & Johnson

      11-K - JOHNSON & JOHNSON (0000200406) (Filer)

      6/23/25 9:41:23 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Johnson & Johnson filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - JOHNSON & JOHNSON (0000200406) (Filer)

      6/10/25 5:06:51 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Vicarious Surgical Announces Election of New Directors

      Vicarious Surgical Inc. (NYSE:RBOT, RBOT WS)) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the election of Fuad Ahmad and Joseph Doherty to the Vicarious Surgical Board of Directors at the Company's 2025 Annual Meeting of Stockholders held on June 27, 2025. The Company also announced the departure of Ric Fulop from the Vicarious Surgical Board of Directors effective as of the Annual Meeting. "On behalf of the board, I am thrilled to welcome Fuad and Joseph to the Vicarious team. Their decades of experience and insight will be instrumental as we continue our advance towards our clinical trial and th

      6/30/25 6:45:00 AM ET
      $GSAT
      $IRIX
      $JNJ
      $MITK
      Telecommunications Equipment
      Consumer Discretionary
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • IMAAVY™ (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published indirect treatment comparison (ITC)

      The ITC compared all published Phase 3 data of these treatments, leveraging longitudinal results, and findings reinforce the importance of consistent, sustained disease control in managing a chronic autoantibody disease like gMG IMAAVY, an FcRn blocker, received U.S. FDA approval earlier this year for the broadest population of individuals living with gMG, including anti-AChR and anti-MuSK antibody positive adults and pediatric gMG patients aged 12 and older SPRING HOUSE, Pa., June 23, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced new data from an indirect treatment comparison (ITC) that showed consistent and sustained disease control with IMAAVY™ (nipocalimab-aahu) versu

      6/23/25 7:32:00 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Johnson & Johnson Hit With $8M Verdict in Massachusetts Mesothelioma Talc Lawsuit

      Jury concludes J&J concealed the danger of its asbestos-laced talcum powder that caused woman's cancer A Suffolk County jury has awarded $8 million in favor of Janice Paluzzi, a Massachusetts woman who developed mesothelioma after decades of using Johnson & Johnson's (NYSE:JNJ) talcum powder products. The jury found the pharmaceutical giant liable for negligence and breach of warranty, concluding that the company's asbestos-contaminated talcum powder products caused Paluzzi's terminal cancer. During the trial, the Dean Omar Branham Shirley legal team, which represented Ms. Paluzzi, presented extensive evidence showing that Johnson & Johnson had internal knowledge of asbestos in its ta

      6/18/25 6:43:00 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care